GSA Capital Partners LLP Buys New Shares in Teladoc Health, Inc. (NYSE:TDOC)

GSA Capital Partners LLP purchased a new stake in shares of Teladoc Health, Inc. (NYSE:TDOC) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,016 shares of the health services provider’s stock, valued at approximately $92,000.

A number of other hedge funds also recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in Teladoc Health in the first quarter worth about $100,000. Gabelli Funds LLC lifted its holdings in Teladoc Health by 10.1% during the 1st quarter. Gabelli Funds LLC now owns 22,970 shares of the health services provider’s stock valued at $347,000 after purchasing an additional 2,100 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Teladoc Health by 6.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 86,377 shares of the health services provider’s stock worth $1,305,000 after buying an additional 5,188 shares during the last quarter. Invenomic Capital Management LP acquired a new stake in shares of Teladoc Health during the first quarter worth approximately $2,819,000. Finally, Virtu Financial LLC acquired a new stake in shares of Teladoc Health during the first quarter worth approximately $523,000. Institutional investors own 76.82% of the company’s stock.

Analyst Upgrades and Downgrades

TDOC has been the topic of a number of research analyst reports. DA Davidson decreased their price target on Teladoc Health from $12.00 to $8.00 and set a “neutral” rating on the stock in a research report on Thursday, August 1st. Piper Sandler lowered their price objective on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. JPMorgan Chase & Co. reduced their price target on Teladoc Health from $16.00 to $9.00 and set a “neutral” rating on the stock in a research report on Monday, August 26th. Truist Financial reduced their price objective on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating on the stock in a research note on Friday, August 2nd. Finally, The Goldman Sachs Group initiated coverage on Teladoc Health in a report on Friday, November 15th. They issued a “buy” rating and a $14.00 price target for the company. Fourteen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Teladoc Health has an average rating of “Hold” and a consensus price target of $12.08.

Insiders Place Their Bets

In other news, COO Michael Willem Waters sold 4,218 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total value of $30,200.88. Following the completion of the transaction, the chief operating officer now directly owns 78,309 shares in the company, valued at approximately $560,692.44. The trade was a 5.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas Mckinley acquired 4,000 shares of the stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $7.69 per share, with a total value of $30,760.00. Following the completion of the transaction, the director now owns 39,077 shares of the company’s stock, valued at approximately $300,502.13. This represents a 11.40 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 20,051 shares of company stock worth $143,565 in the last quarter. Corporate insiders own 0.95% of the company’s stock.

Teladoc Health Stock Up 13.2 %

Teladoc Health stock opened at $12.02 on Tuesday. Teladoc Health, Inc. has a fifty-two week low of $6.76 and a fifty-two week high of $22.54. The firm has a market capitalization of $2.07 billion, a PE ratio of -2.08 and a beta of 0.90. The company’s 50-day moving average is $9.18 and its 200-day moving average is $9.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.10. The company had revenue of $640.51 million for the quarter, compared to the consensus estimate of $630.50 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. Sell-side analysts anticipate that Teladoc Health, Inc. will post -1.16 earnings per share for the current year.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.